Collaboration Against Pain
Milan - Newron Pharmaceuticals, Italy, and Zambon Group, Switzerland, announced early in May the signing of a collaboration and licence agreement aimed at discovering, developing and commercializing novel compounds active as sodium and calcium channel blockers for the treatment of pain conditions - a growing market of unmet medical need.
Newron's contribution to the collaboration is based on its experience in the area of ion channels and will include the licensing of selected Newron proprietary structures to Zambon Group, an international pharmaceutical and chemical company. Zambon Group will contribute to the success of the joint-project with a strong involvement of its research facilities located in Switzerland dedicated to drug discovery. The collaboration will take advantage of Zambon Group's expertise in lead optimization and in all phases of pharmaceutical development.